Drug Trial Radar · NCT06309355
Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Jun 19, 2024
Primary completion
Nov 20, 2025
Study completion Nov 20, 2025
Sponsor
- Lead sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis
Conditions
- Atopic Dermatitis
Interventions
YR001 ointmentDrug
The intervention is YR001 ointment on a range of body surface area for multiple topical administration
PlaceboOther
The intervention is Placebo on a range of body surface area for multiple topical administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint will be safety. Specifically, the primary endpoint will be the incidence of treatment-related AEs (TRAEs) through Day 50.Time frame: Day1-Day 50
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Encore Medical Research -Boynton Beach
Boynton Beach, Florida
Encore Medical Research-Hollywood
Hollywood, Florida
Encore Medical Research-Weston
Weston, Florida
DelRicht Research
Baton Rouge, Louisiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.